Analyze.
Reset.
Revolutionize.

Virtual KOL Event Replay
'1104: A First-in-Class Peptide for Eosinophilic Esophagitis (EoE) and Allergic Disease
Recorded on Tuesday, August 29, 2023
About
If you’re looking for a typical biotechnology company, you’ve come to the wrong place.
We are a revolutionary biotherapeutics company and our mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission.
How?
By developing therapies that achieve superior long-term disease remission from less frequent chronic dosing and without suppression of the immune system. A goal that others haven’t been able to reach.Why?
Existing therapies for autoimmune and allergic diseases require frequent chronic dosing, provide only short-term disease remission in a limited number of patients and suppress the immune system, ultimately putting patients at risk of developing serious infections and life-threatening side effects.Product Development Landscape
Product Development Landscape
Our two platform drug candidates, ‘1104 and ‘1805, reset the immune system after only a single administration in an unmatched way. They have demonstrated unique efficacy and safety in preclinical and human studies – without immune suppression. Given our disease-agnostic approach, we are uniquely positioned as revolutionaries in the development of drugs for various autoimmune and allergic diseases.

news
Latest News
November 7, 2023 | Press Release
Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference
October 25, 2023 | Press Release
Revolo Biotherapeutics Announces Data from Study of ‘1104 in Atopic Adults
Investors
Revolo Bio is a privately held, venture-funded biotechnology firm engaged in unique and revolutionary therapies. If you’d like to get more information, we’d love to provide it, so don’t hesitate to contact us!
Join Us
Contact Us
We are always looking to revolutionize treatment paradigms and are happy to chat with you about yours or ours. Interested? We are!